Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CA7 | P43166 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 9/20 | 0.45 |
| ▸ | CTSS | P25774 | 5/20 | 0.45 |
| ▸ | CTSL | P07711 | 2/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25278428 | 1.00 | CA1 (0.51) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL30080061 | 1.00 | CA1 (0.51) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL22337395 | 1.00 | CA1 (0.51) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL25231724 | 1.00 | CA1 (0.51) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL31605894 | 1.00 | CA1 (0.51) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL13744904 | 0.89 | CA1 (0.51) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL19021911 | 0.86 | CA1 (0.58) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL902049 | 0.86 | CA1 (0.58) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL2849144 | 0.85 | CA1 (0.51) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL23143038 | 0.83 | CA1 (0.50) | CA1CA2CA7CYP2D6CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4729127-A2 | BCL6 INHIBITORS | Cancer Research Technology Limited (GB) | 2026-04-22 | — | — | EP | disclosed |
| US-20260042776-A1 | BCL6 INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2026-02-12 | — | — | US | disclosed |
| US-12486285-B2 | BCL6 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-12-02 | — | — | US | disclosed |
| US-20230287003-A1 | BCL6 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-09-14 | — | — | US | disclosed |
| EP-4201939-A1 | BCL6 INHIBITORS | Cancer Research Technology Limited (GB) | 2023-06-28 | — | — | EP | disclosed |
| EP-3774817-B1 | BCL6 INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2022-12-07 | — | — | EP | disclosed |
| US-11512095-B2 | BCL6 inhibitors | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2022-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287003-A1 | BCL6 INHIBITORS | BCL6, BCL6B, BCL3 | CA1 4244/4885CA2 4379/4885CA7 4068/4885 |
| US-12486285-B2 | BCL6 inhibitors | BCL6, BCL6B, BCL3 | CA1 4244/4885CA2 4379/4885CA7 4068/4885 |
| US-11512095-B2 | BCL6 inhibitors | BCL6, BCL6B, BCL3 | CA1 4244/4885CA2 4379/4885CA7 4068/4885 |
| US-20260042776-A1 | BCL6 INHIBITORS | BCL6, BCL6B, BCL9 | CA1 3824/4885CA2 3076/4885CA7 3694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.